A new dendritic cell vaccine platform known as PROTEXI redirects pre-existing antiviral immune memories from SARS-CoV-2 infections or vaccinations to help the immune system recognize and eliminate therapy-resistant tumors, according to a study published in Nature Communications by researchers from Celloram Inc, University Hospitals, and Case Western Reserve University.
Redirecting Pandemic Immunity Against Solid Tumors
Researchers have developed a novel cancer vaccine platform designed to solve a historic hurdle in oncology. Traditional cancer vaccines often fail to generate strong immune reactions in “immune-cold” tumors. The PROTEXI platform bypasses this limitation by tapping into the mass immune memory generated globally by the COVID-19 pandemic, according to the study published in Nature Communications.
“Rather than inventing a completely new immune response, we are enhancing the ability of the immune system to recognize cancer by leveraging anti-viral memories it already has,” said Tej Pareek, chief executive officer of Celloram Inc.
The underlying mechanism pairs tumor-specific antigens directly with helper signals derived from SARS-CoV-2 Spike protein epitopes. These epitopes consist of small fragments already recognized by immune systems primed through prior vaccination or viral exposure. By coupling these elements, the platform converts dormant antiviral memory into an active, targeted attack against cancer cells.
Preclinical Results in Melanoma and Breast Cancer Models
Testing in preclinical models of melanoma and breast cancer demonstrated that the vaccine effectively slowed tumor growth and improved overall survival rates, according to the study findings. Furthermore, the platform successfully converted tumors that typically evade immune detection into lesions susceptible to immune attack. Researchers also validated the platform’s effectiveness using humanized mouse models built with immune cells donated by individuals who received a COVID-19 vaccine.
“The preclinical data exceeded our expectations. PROTEXI not only enhanced tumor-specific immune responses but also reshaped the tumor microenvironment, expanded immune memory, and improved responses in models resistant to current therapies,” said Seunghwan Lim, vice president of research and operations at Celloram Inc.
The platform relies on pre-existing antiviral CD4+ helper T-cell immunity to reinforce tumor-specific CD8+ cytotoxic T-cell responses. This interaction produces a more coordinated and durable antitumor response than conventional dendritic cell vaccines achieve on their own.
Preparing for First-in-Human Clinical Trials in Sarcoma
Celloram and University Hospitals Cleveland Medical Center are advancing the platform toward initial human clinical evaluations. The upcoming trial will enroll patients with sarcoma, a disease category frequently resistant to conventional treatments, to assess the safety and immunologic activity of the personalized vaccine approach.
“For decades, researchers have recognized the importance of helper T cells in generating durable antitumor immunity, yet identifying clinically useful helper signals has remained a major challenge,” said John Letterio, director of the angie fowler adolescent and young adult cancer institute at University Hospitals Rainbow Babies & Children’s Hospital and co-leader of the developmental therapeutics program of the Case Comprehensive Cancer Center.
If clinical evaluations succeed, investigators suggest the technology could expand to cover a broad spectrum of therapy-resistant cancers. Funding for the research was provided by the Case Comprehensive Cancer Center and the National Cancer Institute of the National Institutes of Health (NIH).
“What is particularly elegant about PROTEXI is that leverages one of the most powerful biological resources already present within the human population: pre-existing antiviral immune memory,” said Seong-Jin Kim, co-founder of Celloram and chairman of MedPacto Inc.
Did You Know?
The PROTEXI platform is designed to use dendritic cells—specialized messenger cells of the immune system—to present tumor antigens alongside SARS-CoV-2 Spike protein fragments, effectively tricking the body’s existing antiviral defenses into fighting cancer cells.
Frequently Asked Questions
What is the PROTEXI platform?
PROTEXI is a dendritic cell cancer vaccine platform developed by researchers from Celloram Inc, University Hospitals, and Case Western Reserve University that redirects pre-existing antiviral immunity from SARS-CoV-2 to target tumors.
How does COVID-19 immunity help fight cancer in this study?
The vaccine pairs tumor-specific antigens with helper signals from SARS-CoV-2 Spike protein epitopes, activating pre-existing CD4+ helper T cells to strengthen the body’s CD8+ cytotoxic T-cell response against cancer cells.
What types of cancer will be tested in the upcoming clinical trials?
Researchers plan to evaluate the personalized vaccine in first-in-human clinical trials involving patients with sarcoma.
Who funded the research?
The study was supported by the Case Comprehensive Cancer Center and the National Cancer Institute of the National Institutes of Health (NIH), with findings published in Nature Communications.
Stay Updated on Cancer Research Breakthroughs
Explore our latest coverage on oncology innovations, clinical trials, and immunotherapy advancements. Subscribe to our newsletter to receive verified medical research updates directly in your inbox.